Home Biosimilar Antibodies Immunology & Inflammation CD markers Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134)
For research use only. Not for use in humans.

Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134)

Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD.

Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134)

Quality Control

Batch: A291401 Purity: 99% Protein concentration: 4.73mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD.
References

Product Details

CAS No. 2225940-98-5
Molecular Weight 144.18
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04198766 RECRUITING Drug: INBRX-106 - Hexavalent OX40 agonist antibody|Drug: pem Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer Inhibrx Biosciences, Inc 2019-12-10 PHASE1; PHASE2
NCT06353997 RECRUITING Drug: Pembrolizumab|Drug: INBRX-106 Triple Negative Breast Cancer Providence Health & Services 2024-09-05 PHASE2
NCT03971409 ACTIVE_NOT_RECRUITING Drug: Avelumab|Drug: Binimetinib|Drug: Liposomal Doxorubicin Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Breast Carcinoma Laura Huppert, MD, BA 2019-07-08 PHASE2
NCT07461181 ACTIVE_NOT_RECRUITING Locally Advanced or Metastatic Solid Tumors Ruijin Hospital 2024-12-30 PHASE1; PHASE2
NCT03092856 ACTIVE_NOT_RECRUITING Drug: Axitinib Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Cancer; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer University of Southern California 2017-07-19 PHASE2
NCT04714983 SUSPENDED Liver Metastases; Liver Metastasis Colon Cancer; Colorectal Cancer; Breast Cancer; Gastric Cancer; Periampullary Cancer; Melanoma; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors DNAtrix, Inc. 2021-02-15 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.